References
- global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Available from: www.goldcopd.org. Published 2016Accessed July 22, 2016
- Glaxo Group LimitedSummary of Product Characteristics: Relvar Ellipta 92 micrograms/22 Micrograms Inhalation Powder, Pre-DispensedBrentford, Middlesex, UK2013 Available from: http://ec.europa.eu/health/documents/community-register/2013/20131113127002/anx_127002_en.pdfAccessed October 23, 2016
- AstraZeneca UK LimitedSummary of Product Characteristics: Symbicort Turbohaler 200/6 Inhalation PowderLuton, Bedfordshire, UKAstraZeneca UK Limited2015
- PatelJMapelDWRobertsMHTime to treatment augmentation among patients with chronic obstructive pulmonary disease (COPD) newly initiated on long-acting muscarinic agents (LAMA) or inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) combination therapyAm J Respir Crit Care Med2015191supplA5774
- BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis20151012207221726527869
- PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
- YangIAClarkeMSSimEHAFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane database Syst Rev20127CD00299122786484
- VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
- WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
- RossiAvan der MolenTDel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J2014441548155625359348
- RossiAGuerrieroMCorradoAOn behalf of the OPTIMO/AIPO Study GroupWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
- MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
- KardosPVogelmeierCBuhlRCriéeC-PWorthHThe prospective non-interventional DACCORD Study in the National COPD Registry in Germany: design and methodsBMC Pulm Med2015151225578330
- WorthHBuhlRCriéeCPKardosPMailänderCVogelmeierCThe “real-life” COPD patient in Germany: the DACCORD studyRespir Med2016111647126775251
- BuhlRCriéeC-PKardosPA year in the life of German patients with COPD: the DACCORD observational studyInt J Chron Obstruct Pulmon Dis20161111639164627499620
- WedzichaJACalverleyPMASeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
- KarlohMFleig MayerAMauriciRPizzichiniMMMJonesPWPizzichiniEThe COPD assessment test: what do we know so far?: a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stagesChest2016149241342526513112
- CalverleyPMAAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
- KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane database Syst Rev20143CD01084424671923
- KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD010115
- NadeemNJTaylorSJCEldridgeSMWithdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodologyRespir Res20111210721838890